INCPF Dividend: InnoCare Pharma Ltd Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

INCPF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	1,321	1,009	738	625	1,043	1
Revenue Growth (YoY)	215%	37%	18%	-40%	104,200%	--
Cost of Revenue	174	138	128	143	65	0
Gross Profit	1,146	871	610	482	977	1
Selling, General & Admin	674	584	539	602	429	152
Research & Development	842	737	691	596	699	391
Operating Expenses	1,476	1,392	1,282	1,212	1,143	495
Other Non Operating Income (Expenses)	-1	-1	6	0	1	-1
Pretax Income	-215	-452	-644	-893	-20	-391
Income Tax Expense	5	0	1	0	46	0
Net Income	-208	-440	-631	-886	-64	-391
Net Income Growth	-20%	-30%	-28.99%	1,284%	-84%	--
Shares Outstanding (Diluted)	1,212.37	1,694.74	1,706.11	1,764.32	1,764.32	1,764.32
Shares Change (YoY)	-19%	-1%	-3%	0%	0%	--
EPS (Diluted)	-0.17	-0.26	-0.37	-0.5	-0.03	-0.22
EPS Growth	6%	-30%	-26%	1,273%	-84%	--
Free Cash Flow	-192	-443	-920	-860	-4	-526
Free Cash Flow Per Share	-0.15	-0.26	-0.53	-0.48	0	-0.29
Gross Margin	86.75%	86.32%	82.65%	77.12%	93.67%	100%
Operating Margin	-24.9%	-51.63%	-91.05%	-116.8%	-15.81%	-49,400%
Profit Margin	-15.74%	-43.6%	-85.5%	-141.76%	-6.13%	-39,100%
Free Cash Flow Margin	-14.53%	-43.9%	-124.66%	-137.6%	-0.38%	-52,600%
EBITDA	--	-424	-585	-660	-123	-455
EBITDA Margin	--	-42.02%	-79.26%	-105.6%	-11.79%	-45,500%
D&A For EBITDA	--	97	87	70	42	39
EBIT	-329	-521	-672	-730	-165	-494
EBIT Margin	-24.9%	-51.63%	-91.05%	-116.8%	-15.81%	-49,400%
Effective Tax Rate	-2.32%	0%	-0.15%	0%	-229.99%	0%